Merit Medical Systems, Inc. (NASDAQ:MMSI) Shares Purchased by CreativeOne Wealth LLC

CreativeOne Wealth LLC raised its position in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 190.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,433 shares of the medical instruments supplier's stock after purchasing an additional 10,113 shares during the quarter. CreativeOne Wealth LLC's holdings in Merit Medical Systems were worth $1,493,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MMSI. NewSquare Capital LLC acquired a new stake in Merit Medical Systems during the 4th quarter valued at $32,000. Kohmann Bosshard Financial Services LLC bought a new position in Merit Medical Systems in the 4th quarter valued at approximately $52,000. Federated Hermes Inc. boosted its position in Merit Medical Systems by 139.1% in the fourth quarter. Federated Hermes Inc. now owns 655 shares of the medical instruments supplier's stock valued at $63,000 after buying an additional 381 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Merit Medical Systems by 237.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier's stock worth $134,000 after buying an additional 977 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Merit Medical Systems by 14.7% during the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier's stock valued at $144,000 after acquiring an additional 191 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Fred P. Lampropoulos sold 31,320 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the completion of the sale, the chief executive officer now directly owns 1,086,028 shares of the company's stock, valued at approximately $112,794,868.08. This trade represents a 2.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian G. Lloyd sold 30,000 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $102.90, for a total transaction of $3,087,000.00. Following the completion of the sale, the insider now directly owns 38,945 shares of the company's stock, valued at approximately $4,007,440.50. This trade represents a 43.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,132 shares of company stock worth $11,139,521. 3.70% of the stock is owned by corporate insiders.

Merit Medical Systems Stock Performance

MMSI stock traded down $1.75 during midday trading on Monday, reaching $89.14. 85,590 shares of the company's stock traded hands, compared to its average volume of 484,194. The stock's 50-day moving average is $100.15 and its 200 day moving average is $100.68. The stock has a market cap of $5.27 billion, a P/E ratio of 43.70, a PEG ratio of 2.34 and a beta of 0.85. Merit Medical Systems, Inc. has a 52-week low of $71.57 and a 52-week high of $111.45. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Wells Fargo & Company reduced their target price on shares of Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Canaccord Genuity Group dropped their target price on shares of Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Barrington Research reaffirmed an "outperform" rating and set a $111.00 price target on shares of Merit Medical Systems in a research report on Friday, April 11th. JPMorgan Chase & Co. began coverage on Merit Medical Systems in a report on Friday, March 28th. They issued an "overweight" rating and a $120.00 target price for the company. Finally, Raymond James increased their price target on Merit Medical Systems from $105.00 to $110.00 and gave the stock an "outperform" rating in a report on Tuesday, December 31st. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $114.33.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.